Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 229 Carcinoma, Non-Small-Cell Lung 115 Glioblastoma 94 Breast Neoplasms 93 Ovarian Neoplasms 88 Carcinoma, Hepatocellular 70 Brain Neoplasms 64 Neoplasm Metastasis 62 Rectal Neoplasms 61 Lung Neoplasms 56 Neoplasms 52 Colonic Neoplasms 52 Glioma 46 Fallopian Tube Neoplasms 35 Carcinoma, Renal Cell 30 Pancreatic Neoplasms 29 Gliosarcoma 29 Melanoma 25 Liver Neoplasms 21 Recurrence 20 Stomach Neoplasms 19 Astrocytoma 19 Adenocarcinoma of Lung 19 Kidney Neoplasms 16 Colorectal Cancer Metastatic 16 Triple Negative Breast Neoplasms 15 Esophageal Neoplasms 15 Uterine Cervical Neoplasms 13 Endometrial Neoplasms 13 Central Nervous System Neoplasms 12

Interventions

nimotuzumab 1 atezolizumab 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡